SCHEMBL23022352

SCHEMBL23022352

COC(=O)c1cccc(S(=O)(=O)Nc2cc(C(F)(F)F)ccc2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.57
ALDH1A1 P00352 4/20 0.56
TSHR P16473 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
PKM P14618 1/20 0.54
ACLY P53396 2/20 0.53
SLC40A1 Q9NP59 1/20 0.53
ERAP1 Q9NZ08 1/20 0.53
LMNA P02545 3/20 0.52
MAPK1 P28482 1/20 0.52
MCL1 Q07820 2/20 0.52
HSD17B2 P37059 1/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
TCF4 P15884 1/20 0.48
CTNNB1 P35222 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22653516 0.88 ERAP1 (0.66) ALDH1A1TSHRACLYERAP1LMNA
SCHEMBL29669997 0.86 NPSR1 (0.49) CYP2C9ALDH1A1TSHRNPSR1ERAP1
SCHEMBL22891786 0.86 NPSR1 (0.49) CYP2C9ALDH1A1TSHRNPSR1ERAP1
SCHEMBL7567314 0.81 NPSR1 (0.59) CYP2C9ALDH1A1NPSR1ACLYSLC40A1
SCHEMBL19065100 0.80 GAA (0.64) ALDH1A1TSHRLMNAHSD17B2POLB
SCHEMBL22891787 0.80 NPSR1 (0.49) ALDH1A1NPSR1ERAP1LMNAMCL1
SCHEMBL7458365 0.79 MEN1 (0.64) PKMACLYERAP1GAAKMT2A
SCHEMBL29670020 0.79 ERAP1 (0.46) ALDH1A1NPSR1ERAP1LMNAMAPK1
SCHEMBL7570517 0.78 CYP2C9 (0.61) CYP2C9ALDH1A1TSHRNPSR1PKM
SCHEMBL22498190 0.78 CACNA1B (0.56) ALDH1A1NPSR1POLBGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016768-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONS CURA THERAPEUTICS, LLC 2024-01-18 US disclosed
US-11701334-B2 Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications CURA THERAPEUTICS, LLC (US) 2023-07-18 US disclosed
US-20210052525-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONS CURA THERAPEUTICS, LLC 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052525-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONS MAPT, PSEN1, PSEN2 CYP2C9 426/4885ALDH1A1 2458/4885TSHR 3698/4885
US-20240016768-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONS MAPT, PSEN1, PSEN2 CYP2C9 426/4885ALDH1A1 2458/4885TSHR 3698/4885
US-11701334-B2 Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications MAPT, PSEN1, PSEN2 CYP2C9 426/4885ALDH1A1 2458/4885TSHR 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.